J Buon
-
The aim of this research was to examine overall (OS) and disease-free survival (DFS) in patients with colorectal peritoneal carcinomatosis (CRC-PC), treated with cytoreductive surgery (CRS) and intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC), as well as to analyse factors of prognostic significance. ⋯ Our study indicates that CRS+HIPEC significantly improves the survival of CRC-PC patients. This treatment modality should be considered as the most suitable in well-selected patients with this disease.
-
Due to the fact that fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) and technetium-99m-methylenediphosphonate ((99m)Tc-MDP) whole body scans identify bone metastases by different mechanisms, i.e. by using glucose metabolism and osteoblastic response in the bone, respectively, it can be expected that there may be some differences between these two methods in the number of lesions identified. The aim of this study was to compare the sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) in detecting bone metastases between (18)F-FDG-PET/CT and conventional (99m)Tc-MDP whole body scans. ⋯ For the detection of bone metastases the specificity and accuracy of (18)F-FDG-PET/CT were higher compared to bone scintigraphy, while the sensitivity was lower. It is the opinion of the authors that both studies are complementary to final diagnosis.
-
Benign and malignant pulmonary lesions are not easy to distinguish in a clinical setting. We investigated the feasibility of using parametric imaging of the rate constant Ki to diagnose the nature of pulmonary lesions. ⋯ Our results indicate that Ki parametric imaging in (18)F-FDG PET/computed tomography (CT) dynamic multi-bed scanning may be useful in the differential diagnosis of pulmonary lesions.
-
Chemotherapy is the conventional treatment for castration-resistant prostate cancer (CRPC) which provides only modest benefits. In the last few years, immunotherapy has emerged as an exciting therapeutic modality for advanced prostate cancer. ⋯ Current trials investigate the role of various immunological approaches in the treatment of prostate cancer, as far as the clinical benefit they provide is concerned and also deal with the issue of the measurability of this benefit. Future studies will focus on the combination of immunotherapeutic agents with conventional treatments in an effort to optimize patient outcomes.
-
To evaluate the efficacy as well as acute and late toxicity of two different accelerated hypofractionated 3D-conformal radiotherapy (Hypo-3DCRT) schedules in patients with bladder cancer. ⋯ Beyond the non-randomized design of the trial, the Hypo-3DCRT schedules used appear to be an acceptable alternative to the traditional longer radiotherapy (RT) schedules for elderly patients unfit for daily irradiation.